gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Coxsackie virus and adenovirus receptor

CAR, adenovirus receptor
Top mentioned proteins: CAN, Cysteinyl-tRNA synthetase, CD19, V1a, HAD
Papers on CAR
Nuclear receptors and drug metabolism for the personalization of cancer therapy.
Toffoli et al., Italy. In Expert Opin Drug Metab Toxicol, Feb 2016
Several studies demonstrated that PXR and CAR activation can affect the expression of genes involved in absorption, distribution, metabolism and excretion (ADME) of antineoplastic drugs.
Deciphering cd137 (4-1bb) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Melero et al., Pamplona, Spain. In Eur J Immunol, Feb 2016
Furthermore, the signaling cytoplasmic tail of CD137 is a key component of anti-CD19 chimeric antigen receptors (CAR) which are used to redirect T cells against leukemia and lymphoma in the clinic.
Quadriceps function relates to muscle size following ACL reconstruction.
Hart et al., Charlottesville, United States. In J Orthop Res, Feb 2016
Clinical factors including International Knee Documentation Committee(IKDC) score, normalized knee extension MVIC torque (Nm/kg) and quadriceps central activation ratio(CAR, %) were assessed in addition to CSA.
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Young et al., Los Angeles, United States. In Proc Natl Acad Sci U S A, Feb 2016
UNASSIGNED: Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical trials for B-cell malignancies.
Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
Eshhar et al., Qiryat Gat, Israel. In Annu Rev Pharmacol Toxicol, Feb 2016
A chimeric antigen receptor (CAR) is a recombinant fusion protein combining an antibody-derived targeting fragment with signaling domains capable of activating T cells.
Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
O'Brien et al., Houston, United States. In Blood Rev, Jan 2016
Strategies targeting the immune system such as lenalidomide, chimeric antigen receptor (CAR) T cells, and more recently, checkpoint inhibitors, are in clinical development.
Efavirenz pharmacogenetics in a cohort of Italian patients.
D'Avolio et al., Torino, Italy. In Int J Antimicrob Agents, Jan 2016
Whole blood was used to identify SNPs in ABCB1, MRP2, CYP2B6, CYP2A6, UGT2B7, NR1I2 (PXR), NR1I3 (CAR) and HNF4α by real-time PCR.
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Kranz et al., Urbana, United States. In Trends Pharmacol Sci, Jan 2016
While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs.
L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
Forman et al., Seattle, United States. In Plos One, Dec 2015
Recent clinical trials have demonstrated the impressive therapeutic potential of adoptive therapy using chimeric antigen receptor (CAR)-redirected T cells to target hematological cancers, and emerging studies suggest a similar impact may be achieved for solid cancers.
Shifting the Evolving CAR T Cell Platform into Higher Gear.
Bluestone et al., San Francisco, United States. In Cancer Cell, Nov 2015
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD28-CD3ζ CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradication while reducing exhaustion.
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Mackall et al., Bethesda, United States. In Nat Med, Jun 2015
It remains unknown whether the impressive effects of CD19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior functionality of the CD19 CAR itself.
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.
Dotti et al., Houston, United States. In Nat Med, May 2015
Adoptive transfer of chimeric antigen receptor (CAR)-redirected T lymphocytes (CAR-T cells) has had less striking therapeutic effects in solid tumors than in lymphoid malignancies.
New cell sources for T cell engineering and adoptive immunotherapy.
Sadelain et al., New York City, United States. In Cell Stem Cell, May 2015
The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability.
The Hematopoietic Niche in Myeloproliferative Neoplasms.
Zeiser et al., Freiburg, Germany. In Mediators Inflamm, 2014
A complex microenvironment adjacent to the marrow vasculature (vascular niche) and close to the endosteum (endosteal niche) harbors multiple cell types including mesenchymal stromal cells and their derivatives such as CAR cells expressing high levels of chemokines C-X-C motif ligand 12 and early osteoblastic lineage cells, endothelial cells, and megakaryocytes.
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rouce et al., Houston, United States. In Front Immunol, 2014
In this review, we will focus on recent advances in the field of NK cell immunotherapy, including augmentation of antibody-dependent cellular cytotoxicity, manipulation of receptor-mediated activation, and adoptive immunotherapy with ex vivo-expanded, chimeric antigen receptor (CAR)-engineered, or engager-modified NK cells.
The coxsackie and adenovirus receptor (CAR) is required for renal epithelial differentiation within the zebrafish pronephros.
Majumdar et al., Stockholm, Sweden. In Dev Biol, 2008
These results establish a requirement for CAR in the terminal differentiation of renal glomerular and tubular cell types.
share on facebooktweetadd +1mail to friends